RNASeq Analysis for Accurate Identification of Fusion Partners in Tumor Specific Translocations Detected by Standard FISH Probes in Hematologic Malignancies.

BACKGROUND

Fluorescence labeled DNA probes and in situ hybridization methods had shorter turn round time for results revolutionized their clinical application. Signals obtained from these probes are highly specific, yet they can produce fusion signals not necessarily representing fusion of actual genes due to other genes included in the probe design. In this study we evaluated discordance between cytogenetic, FISH and RNAseq results in 3 different patients with hematologic malignancies and illustrated the need to perform next generation sequencing (NGS) or RNASeq to accurately interpret FISH results.

METHODS

Bone marrow or peripheral blood karyotypes and FISH were performed to detect recurring translocations associated with hematologic malignancies in clinical samples routinely referred to our clinical cytogenetics laboratory. When required, NGS was performed on DNA and RNA libraries to detect somatic alterations and gene fusions in some of these specimens. Discordance in results between these methods is further evaluated.

RESULTS

For a patient with plasma cell leukemia standard / dual fusion FISH assay detected fusion that was interpreted as -positive leukemia, whereas NGS/RNASeq detected . For a pediatric acute lymphoblastic leukemia patient, a genetic diagnosis of -positive ALL was rendered because the break-apart probe detected clonal rearrangement, whereas NGS detected . A -positive B-prolymphocytic leukemia was rendered for another patient with a cytogenetically identified t(8;14) and by FISH, whereas NGS detected a novel not previously reported.

CONCLUSIONS

These are 3 cases in a series of several other concordant results, nevertheless, elucidate limitations when interpreting FISH results in clinical applications, particularly when other genes are included in probe design. In addition, when the observed FISH signals are atypical, this study illustrates the necessity to perform complementary laboratory assays, such as NGS and/or RNASeq, to accurately identify fusion genes in tumorigenic translocations.